-
Story
Supercharging R&D: How AI helps us to bring medicines to patients faster -
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Press Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Press Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Press Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Press Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Press Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US